Issues regarding the routine and long-term use of growth hormone in anti-aging medicine

Journal of Anti-Aging Medicine

Volumn 4, Issue 4, 2001, Pages 279-300

  Walker, Richard F ^a,b   Bercu, Barry B ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

AGING; ARTICLE; HORMONAL THERAPY; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035574217     PISSN: 10945458     EISSN: None     Source Type: Journal    
DOI: 10.1089/10945450152850623     Document Type: Article

References (126)

1. Effects of human growth hormone in men over 60 years old
2. The war on aging
3. GHRH 129 twice daily reverses the decreased GH and IGF1 levels in old men
4. Gray market. The elderly obtain "rejuvenation" drug via network of doctors
5. Effect of age and obesity on fasting levels of glucose, insulin, glucagons and growth hormone in men
6. Effect of age on growth hormone secretion in man
7. Decline in GH secretion in aging animals and man
8. Pleiotropic effects of growth hormone and insulin-like growth factor (IGF-1) on biological aging: Inferences from moderate caloric-restricted animals
9. Effects of sex and age on 24-hour profile of growth hormone secretion in men: Importance of endogenous estradiol concentrations
10. Age-related changes in the twenty-four-hour spontaneous secretion of growth hormone in normal individuals
11. Nyctohemoral growth hormone profiles in young and aged men: Correlations with somatomedin-C levels
12. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals
13. Effects of progressive resistance training on growth hormone and testosterone levels in young and elderly subjects
14. Metabolic responses to exercise in young and old athletes and sedentary men
15. Human growth hormone and cortisol response to insulin stimulation in aging
16. Effects of sex and age on growth hormone response to growth hormone releasing hormone in healthy individuals
17. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man
18. Age-related changes in plasma growth hormone response to growth hormone-releasing factor in man
19. Repetitive growth hormone-releasing hormone administration restores the attenuated growth hormone (GH) response to GH-releasing hormone testing in normal aging
20. Restoration of normal growth hormone responsiveness to GHRH in normal aged men by infusion of low amounts of theophylline
21. Effectiveness of growth hormone (GH) secretagogues for diagnosing and treating GH secretory deficiency in aging men
22. Growth hormone, body composition and aging
23. The effect of hypopituitarism on life expectancy
24. Premature mortality due to cardiovascular disease in hypopituitarism
25. Increased cerebrovascular mortality in patients with hypopituitarism
26. The growth hormone deficiency syndrome in adults
27. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults
28. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency
29. Body composition in growth hormone-deficient adults
30. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults: Influence of gender and apo(a) and apoE phenotypes
31. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults
32. Cardiac structure and function in growth hormone deficiency
33. Growth hormone treatment in growth hormone deficient adults I. Effects on muscle mass and strength
34. Growth hormone treatment in growth hormone deficient adults. II. Effects on exercise performance
35. Measure quality of life in patients with pituitary disease
36. Mortality in hypopituitary patients
37. Effects of growth hormone replacement in adults
38. Growth hormone and the heart
39. Body composition, bone metabolism and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses
40. Cardiovascular and renal effects of growth hormone
41. Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults
42. The effects of low-dose recombinant human growth hormone on cardiovascular structure and function in hypopituitary growth hormone-deficient adults
43. Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion
44. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency
45. Shortand long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults
46. Cardiovascular aspects of growth hormone replacement therapy in adults
47. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency
48. Growth hormone deficient adults are insulin-resistant
49. Growth hormone treatment reverses early atherosclerotic changes in growth hormone-deficient adults
50. Histomorphometric analysis of bone mass and bone metabolism in growth hormone-deficient adult men
51. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency
52. Effects of 2 years of growth hormone treatment on body composition and cardiovascular risk factors in adults with growth hormone deficiency
53. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis and bone metabolism in adults with acquired GH deficiency: A double blind, randomized, placebo-controlled study
54. Effect of growth hormone replacement on bone mass in adult onset growth hormone deficiency
55. Beneficial effects of 12 months replacement therapy with recombinant human growth hormone to growth hormone deficient adults
56. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adultonset GH deficiency
57. Growth hormone therapy and fracture risk in the growth hormone-deficient adult
58. Growth hormone and bone
59. Bone density at various sites for prediction of hip fracture
60. Longterm fracture prediction by bone mineral assessed at different skeletal sites
61. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency
62. Current therapy for osteoporosis
63. Effects of 42 months of GH treatment on bone density and bone turnover in GH-deficient adults
64. Effect of growth hormone on plasma fatty acids
65. Growth hormone and the metabolism of carbohydrate and lipid in adipose tissue
66. Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men
67. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency
68. Adipose tissue assessed by magnetic resonance imaging in growth hormone-deficient adults: The effect of growth hormone replacement and a comparison with control subjects
69. The effect of low-dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity and cardiovascular risk factors in hypopituitary adults
70. Adipose tissue and muscle volume determination by computed tomography in acromegaly, before and one year after adrenomectomy
71. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH
72. Body composition and tissue distributions in growth hormone deficient adults before and after growth hormone treatment
73. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency
74. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review
75. Two years of growth hormone (GH) treatment increases isometric and isokinetic muscle strength in GH-deficient adults
76. Beneficial effect of growth hormone treatment in GHdeficient adults
77. Decreased plasma and extracellular volume in growth-hormone deficient adults and the acute and prolonged effects of GH administration - A controlled experimental study
78. Maximum anaerobic performance in childhood-onset GH-deficient adults
79. Growth hormone: Neurocrine and neuroendocrine perspectives
80. Characterization of putative growth hormone receptors in human choroids plexus
81. Quality of life in adults with growth hormone (GH) deficiency: Response to treatment with recombinant human GH in a placebo-controlled 21-month trial
82. Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters
83. Rat growth hormone and hypothalamic catecholamine nerve terminal systems. Evidence for rapid and discrete reductions in dopamine and noradrenaline levels and turnover in the median eminence of the hypophysectomized male rat
84. Somatomedin levels in cerebrospinal fluid from adults with pituitary disorders
85. Effects of growth hormone on brain biogenic amine levels
86. Growth hormone-deficient young adults have decreased deep sleep
87. Cognitive impairments and mood disturbances in growth hormone-deficient men
88. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency
89. Effects of growth hormone substitution on mental performance in adults with growth hormone deficiency: A pilot study
90. Cognitive changes during growth hormone replacement in adult men
91. Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: Combined data from 12 European placebo-controlled trials
92. Two years of replacement therapy in adults with growth hormone deficiency
93. Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency
94. Mortality in acromegaly
95. Epidemiology of acromegaly in the Newcastle region
96. Epidemiology and long term survival in acromegaly
97. Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: Combined data from 12 European placebo-controlled clinical trials
98. Safety of growth hormone replacement in adults
99. Body composition in acromegaly
100. Cardiovascular risk factors in adult patients with growth hormone deficiency
101. Na retention with human growth hormone
102. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the rennin-angiotensin system
103. Sodium potassium dependent ATPase in hypophysectomized rats: Response to growth hormone, triiodothyronine and cortisone
104. Using dilution techniques and multifrequency bioelectrical impedance to assess both total body water and extracellular water at baseline and during recombinant human growth hormone (GH) treatment in Gh-deficient adults
105. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: Increase in exercise capacity and normalization of body composition
106. Growth hormone treatment of adults with growth hormone deficiency: Results of a 13-month placebocontrolled cross-over study
107. Does growth hormone prevent or accelerate aging?
108. Moderate caloric restriction prevents the age-related decline in growth hormone receptor signal transduction
109. The effects of growth hormone and IGF-1 deficiency on cerebrovascular and brain ageing
110. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation
111. Antioxidative mechanism and plasma growth hormone levels: Potential relationship in the aging process
112. Catalase expression in delayed and premature aging mouse models
113. Free radical defenses in the liver and kidney of human growth hormone transgenic mice: Possible mechanisms of early mortality
114. Increased glial fibrillary acidic protein (GFAP) levels in the brains of transgenic mice expressing the bovine growth hormone (bGH) gene
115. Growth hormone as a risk for premature mortality in healthy subjects: Data from a paris prospective study
116. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
117. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study
118. Growth hormone treatment induces mammary gland hyperplasia in aging primates
119. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
120. Response: Re: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
121. Insulin-Like growth factor I: Implications in aging